Treatment of triple-negative breast cancer (TNBC) is a challenge to oncologists. Currently, the lack of effective therapy has fostered a major effort to discover new targets and therapeutics to combat this disease. The recepteur d’origine nantais (RON) receptor has been implicated in the pathogenesis of TNBC. Clinical studies have revealed that aberrant RON expression is crucial in regulating TNBC malignant phenotypes. Increased RON expression also has prognostic value for breast cancer progress. These features provide the rationale to target RON for TNBC treatment. In this review, we discuss the importance of RON in TNBC tumorigenesis and the development of anti-RON antibody–drug conjugates (ADCs) for clinical application. The findings from preclinical studies lay the foundation for clinical trials of this novel biotherapeutic for TNBC therapy.

三阴性乳腺癌 (TNBC) 的治疗对肿瘤学家来说是一个挑战。目前，缺乏有效的治疗方法促使人们做出重大努力来发现新的靶点和治疗方法来对抗这种疾病。受体 d'origin nantais (RON) 受体与 TNBC 的发病机制有关。临床研究表明，异常 RON 表达在调节 TNBC 恶性表型中至关重要。RON 表达增加对乳腺癌进展也具有预后价值。这些特征为靶向 RON 用于 TNBC 治疗提供了依据。在这篇综述中，我们讨论了 RON 在 TNBC 肿瘤发生中的重要性以及用于临床应用的抗 RON 抗体-药物偶联物 (ADC) 的开发。临床前研究的结果为这种用于 TNBC 治疗的新型生物疗法的临床试验奠定了基础。